TT

Tessera Therapeutics

www.tesseratherapeutics.com link_icon

Tessera Therapeutics Market Research Report



Company Overview



  • Name: Tessera Therapeutics

  • Mission: To cure disease by writing in the code of life, pioneering Gene Writing™, a new category of genetic medicine.

  • Founded: Tessera Therapeutics was founded in 2018 by Flagship Pioneering.

  • Key People: Michael Severino, M.D., CEO; Cynthia M. Patton, General Counsel and Secretary; Dr. Cecilia Cotta-Ramusino, Senior Vice President of Technology Development and Head of Platform.

  • Headquarters: Somerville, Massachusetts, USA.

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • What the Company is Known For: Tessera Therapeutics is known for developing Gene Writing™ technology, which writes therapeutic messages into the genome to treat diseases at their source.


Products



Gene Writing™



  • Description: A versatile technology platform that makes small and large alterations to the human genome.

  • Key Features:

  • Rewriting: Corrects single nucleotide substitutions and insertions/deletions.

  • Writing Exons: Replaces entire exons at native loci.

  • Writing Whole Genes: Incorporates entire genes into the genome.


RNA Gene Writers



  • Description: Modular RNA-based tools enabling a range of genomic alterations without double-stranded breaks.

  • Key Features:

  • Target Primed Reverse Transcription (TPRT): Efficiently writes DNA using an RNA template.

  • Utilizes RNA-binding, DNA-binding, DNA-nicking, and Reverse Transcription processes.


DNA Gene Writers



  • Description: DNA-based technology for durable genomic alterations.

  • Key Features:

  • Stable integration without introducing double-stranded breaks.

  • Potential for permanent correction, suitable for pediatric cures.


Delivery Platform



  • Description: Proprietary lipid nanoparticle (LNP) technology for RNA delivery.

  • Key Features:

  • Safe and effective nucleic acid delivery.

  • Provides transient expression, reducing genotoxicity risks.

  • Broad safety profile with re-dosable potential.


Recent Developments



New Products/Features



  • RNA-based Lipid Nanoparticle (LNP) Gene Writer System: Enables same-day manufacturing of engineered CAR-T cells demonstrated with in vivo anti-tumor activity.

  • Gene Writers and LNP delivery: Efficient in vivo corrections of phenylketonuria (PKU), alpha-1 antitrypsin deficiency (AATD), sickle cell disease (SCD), and Wilson's Disease (WD).


Recent Partnerships and Collaborations



  • No specific partnerships mentioned.


Recent Developments



  • June 20, 2024: Tessera presented NHP data in AATD program showing ~56% rewriting efficiency in hepatocytes using RNA Gene Writers.

  • May 10, 2024: Tessera presented advancements with new preclinical data showcasing up to 50% correction efficiency in AATD and significant in vivo rewriting for SCD in humanized mice.

  • April 22, 2024: Announced presentations for new data on preclinical programs at the American Society of Gene and Cell Therapy Annual Meeting.


Conclusion



Tessera Therapeutics stands at the forefront of genetic engineering with its pioneering Gene Writing™ technology. The company aims to expand the possibilities in genetic medicine by providing permanent solutions to genetic diseases through advanced RNA and DNA Gene Writers and an innovative non-viral LNP delivery platform. The company's latest clinical progress points towards transformative potential in treating complex genetic conditions with high fidelity and significant therapeutic impacts.